Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Gvoke comes in three forms for subcutaneous injection: HypoPen auto-injector prefilled syringe prefilled vial and syringe kit To find out what the cost of Gvoke will be for you, talk with your ...

The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the ...

Key products include Gvoke for severe hypoglycemia, Keveyis for Primary Periodic Paralysis, and Recorlev for Cushing's Syndrome, with Recorlev showing strong growth. The company has a promising ...

InvestingPro analysis reveals 8 additional key insights about the company’s potential. Gvoke VialDx™ is designed to temporarily inhibit gastrointestinal movement during diagnostic procedures ...